Last reviewed · How we verify
MHB036C
At a glance
| Generic name | MHB036C |
|---|---|
| Sponsor | Minghui Pharmaceutical (Hangzhou) Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of MHB036C for Advanced Solid Tumor (PHASE1, PHASE2)
- A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors (PHASE2)
- A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer (PHASE1, PHASE2)
- Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MHB036C CI brief — competitive landscape report
- MHB036C updates RSS · CI watch RSS
- Minghui Pharmaceutical (Hangzhou) Ltd portfolio CI